Lee Larcombe
CEO & Co-founder
Computational biologist; PhD in synthetic antigen design for antibody development.
Our Approach
Alternative splicing generates disease-specific protein variations and is often hijacked in cancer, creating unique, actionable targets that remain untapped by conventional therapies.
By identifying and drugging these cancer-specific isoforms, we aim to selectively attack and kill tumor cells, offering new hope for patients who currently have no effective options.
Our programmes are targeting
Our Team
Sarah Morgan
CSO & Co-founder
Translational biologist; PhD in variant splice targets in cancer; MA in healthcare law and ethics.
Emilie Syed
Investor Director
Venture builder; PhD in neuroscience.
Isabella Garcia
Discovery Lead
PhD in isoform-specific alternative splicing.
Jurgen Moll
Scientific Advisor
Oncology drug discovery: Boehringer-Ingelheim, Sanofi, Pfizer.
Mark Bailey;
Venture Partner
Founder, biotech leader and advisor.
Our Mission
We are building therapies for patients that current medicines leave behind.
Everyone deserves precise and effective medicines that work:
On target. On time. Every time.